Attenzione: Ci siamo trasferiti. Non è più possibile acquistare i prodotti Merck Millipore nel sito MerckMillipore.comPer saperne di più

420146 JAK3 Inhibitor VIII, NSC114792 - Calbiochem

420146
Purchase on Sigma-Aldrich

Panoramica

Replacement Information

Tabella delle specifiche principali

Empirical Formula
C₂₆H₃₂N₄O₂S

Products

Numero di catalogoConfezionamento Qtà/conf
420146-10MG Bottiglia di vetro 10 mg
Description
OverviewA cell-permeable steroidal-purinethione that targets JAK3 kinase domain and selectively inhibits JAK3, but not JAK1, JAK2, or TYK2, activity and effectively blocks the constitutive Jak3 and STAT5 phosphorylations (complete inhibition at 10 µM) in BaF3-JAK3V674A and BLNK-/- BKO84 culltures. Shown to prevent the JAK3-dependent survival of L540, BaF3-JAK3WT, BaF3-JAK3V674A, and BLNK-/- BKO84 cells (by 40%, 50%, 57%, and 85%, respectively; 20 µM; 72 h), while exhibiting no effect against the JAK3-independent growth in DU145, HDLM-2, and MDA-MB-468 cultures.
Catalogue Number420146
Brand Family Calbiochem®
Synonyms10,13-Dimethyl-17-(2-(6-sulfanylidene-3H-purin-9-yl)acetyl)-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one, Dimethyl-sulfanylidene-purinyl-acetyl-dodecahydrocyclopenta[a]phenanthren-3-one
References
ReferencesKim, B.H., et al. 2010. Mol. Cancer 9, 36.
Product Information
FormYellowish-white powder
Hill FormulaC₂₆H₃₂N₄O₂S
Chemical formulaC₂₆H₃₂N₄O₂S
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Purity≥99% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications

Documentation

JAK3 Inhibitor VIII, NSC114792 - Calbiochem MSDS

Titolo

Scheda di sicurezza (MSDS) 

Riferimenti bibliografici

Panoramica delle referenze
Kim, B.H., et al. 2010. Mol. Cancer 9, 36.

Informazioni tecniche

Titolo
JAK/STAT Signaling Research Focus
Scheda tecnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision22-November-2012 JSW
Synonyms10,13-Dimethyl-17-(2-(6-sulfanylidene-3H-purin-9-yl)acetyl)-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one, Dimethyl-sulfanylidene-purinyl-acetyl-dodecahydrocyclopenta[a]phenanthren-3-one
DescriptionA cell-permeable steroidal-purinethione compound that targets JAK3 kinase domain and selectively inhibits JAK3, but not JAK1, JAK2, or TYK2, activity in cell-free immuncomplex kinase assays, and effectively blocks the constitutive Jak3 and STAT5 phosphorylations (complete inhibition at 10 µM) in BaF3-JAK3V674A and BLNK-/- BKO84 culltures. Shown to prevent the JAK3-dependent survival of L540, BaF3-JAK3WT, BaF3-JAK3V674A, and BLNK-/- BKO84 cells in a time- and dose-dependent manner (by 40%, 50%, 57%, and 85%, respectively, after 72 h incubation with 20 µM inhibitor), while exhibiting no effect against the JAK3-independent growth in DU145, HDLM-2, and MDA-MB-468 cultures.
FormYellowish-white powder
Intert gas (Yes/No) Packaged under inert gas
Chemical formulaC₂₆H₃₂N₄O₂S
Structure formulaStructure formula
Purity≥99% by HPLC
SolubilityDMSO (10 mg/ml)
Storage +2°C to +8°C
Protect from light
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Standard Handling
ReferencesKim, B.H., et al. 2010. Mol. Cancer 9, 36.